Physician profile
John Kelemen
NPI 1811973449
$151,785.39
in general payments reported to CMS, 2019-2025
59 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,678 · 2021: $34K · 2022: $36K · 2023: $21K · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $11K · Travel and Lodging: $2,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,962.50 |
| Food and Beverage | $10,792.78 |
| Travel and Lodging | $2,818.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $69,177.23 | 2019-2022 | |
| Abbvie INC. | $64,793.52 | 2021-2025 | |
| Pfizer INC. | $6,706.32 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,124.25 | 2023-2025 | Hyqvia |
| Argenx US, INC. | $994.39 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $841.24 | 2019-2025 | Ultomiris |
| Intuitive Surgical, INC. | $798.77 | 2023 | Da Vinci Surgical System |
| Harmony Biosciences LLC | $555.94 | 2022-2025 | Wakix |
| Sk Life Science, INC. | $512.84 | 2022-2025 | |
| Merz Pharmaceuticals, LLC | $480.89 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Lundbeck LLC | $458.85 | 2022-2025 | Vyepti |
| Grifols USA, LLC | $408.45 | 2022-2025 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $400.46 | 2023-2025 | Dysport |
| Ucb, INC. | $364.85 | 2022-2025 | Rystiggo, Fintepla |
| Neurocrine Biosciences, INC. | $354.54 | 2022-2025 | Ingrezza, Ongentys |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelemen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.